OncoTherapy Science, Inc. announced a private placement and entered into a subscription agreement to issue 2,000,000 common shares at an issue price ¥45 per share for gross proceeds of ¥90,000,000, 230,000 34th stock acquisition rights at a price of ¥20 per stock acquisition rights for gross proceeds of ¥4,600,000 and 150,000 35th stock acquisition rights at a price of ¥9 per stock acquisition rights for gross proceeds of ¥1,350,000 for aggregate gross proceeds of ¥95,950,000 on March 24, 2023. The will include participation from Long Corridor Alpha Opportunities Master Fund for 1,600,000 common shares, 184,000 units of 34th stock acquisition rights and 120,000 units of 35th stock acquisition rights and LMA SPC - MAP 246 Segregated Portfolio for 400,000 common shares, 46,000 units of 34th stock acquisition rights and 30,000 units of 35th stock acquisition rights. The transaction has been approved by the board of directors.

The company is expected to close the transaction on April 10, 2023.